Increasing the predictive and translational value of preclinical studies.
Biomarkers are distinctive biological characteristics that can predict pathology early in disease as well as enhance mechanistic understanding of disease. Biomarkers are useful in preclinical studies since they are objectively measured as an indication of normal biological processes, pathogenic processes, or pharmacological responses to therapeutic treatments. Utilizing clinically relevant biomarkers in preclinical studies enhances the predictive value of the data.
MD Biosciences is experienced in biomarker analysis, including methods that enable reverse-translation from the clinic. Examples of some of the methods we regularly incorporate into studies is listed below. We also have extensive experience in assay development and validation for CNS research.
Circulating biomarkers using ELISA:
- Neuro-specific enolase NSE
- Protein S-100B
- Ubiquitin C terminal hydrolase 1 (UCHL1)
- Neurofilament light chain NfL
- Tau protein
- Glial fibrillary acidic protein GFAP
DAMP and PAMP assays
- Tissue samples (from diseased and naive amimals) for biomarker research
- Blood samples (from diseased and naive animals) for biomarker research
- P25 for pain
- Biomarkers in blood and tissue samples
Example Flow Cytometry Analysis
CD4, Th1, Th17, Treg were anlayzed in spleen and spinal cord samples from a mouse MOG-EAE study.
Ready to discuss your project?
If you are ready to discuss how electrophysiology can add to your understanding of your therapeutic potential, our scientists are eager to explore the possibilities with you. Like many other pharmaceutical and medical device developers, you can rely on predictive preclinical data.